Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosimilar Litigation Trends: Settlements, Declaratory Judgment Rejections, Congressional Intervention

Executive Summary

Of the 27 suits brought so far, four have resulted in patent settlements; restarting patent dance is new trend for ongoing litigation.

You may also be interested in...



Keeping Track: Yupelri Is Latest Novel Drug Approved, But Bad News For Biosimilars

The latest drug development news and highlights from our US FDA Performance Tracker.

AbbVie Inks Sixth Humira Biosimilar Settlement, Battles Boehringer's 'Unclean Hands' Claim

Boehringer stands out in its decision to litigate rather than settle, and the firm has obtained AbbVie's settlement agreements with other biosimilar makers.

AbbVie Inks Sixth Humira Biosimilar Settlement, Battles Boehringer's 'Unclean Hands' Claim

Boehringer stands out in its decision to litigate rather than settle, and the firm has obtained AbbVie's settlement agreements with other biosimilar makers.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM013626

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel